ai3Bio's Th17 Elimination Thesis: Mechanistic Novelty Without Clinical Validation — A High-Risk Preclinical Bet

ai3Bio Launches with $48M to Pursue Novel Immune Reset Therapies

ai3Bio, a new biotechnology startup formed from Corner Therapeutics and Novasenta, has launched with $48 million in Series A funding to develop novel therapies for autoimmune diseases. Headquartered in Pittsburgh and Watertown, the company aims to "reset" the immune system by selectively eliminating Th17 cells, a subset of T helper cells implicated in inflammation, rather than broadly suppressing the immune system or depleting B cells. Its preclinical pipeline includes two distinct approaches: one utilizing microscopic fatty shells for molecular delivery and another employing a targeted antibody drug, both demonstrating potent efficacy in early testing.

• ai3Bio officially launched on September 29, 2026, securing $48 million in a Series A venture capital round. This funding was led by UPMC Enterprises and Ziff Capital Partners, with additional investment from Cockrell Partners and Tanis Ventures, establishing the company's financial foundation for advancing its innovative autoimmune disease pipeline.
• The company's core innovation lies in its approach to autoimmune diseases, focusing on the selective elimination of Th17 cells. This strategy contrasts with many current and emerging treatments that target B cells, aiming to provide a more precise "immune reset" by addressing a specific subset of T helper cells responsible for producing the inflammatory cytokine IL-17, thereby avoiding broad immune suppression.
• ai3Bio is developing two distinct therapeutic platforms. One involves delivering molecular instructions via microscopic fatty shells to induce Th17 cell self-destruction, while the other utilizes a targeted antibody drug to facilitate their removal. Preclinical testing has demonstrated that both approaches effectively remove disease-causing Th17 cells and exhibit potent efficacy, with early safety studies currently underway to support future human trials.

Addressing Current Limitations in Autoimmune Disease Treatment

Autoimmune disease management faces persistent challenges across immunogenicity, therapeutic durability, and infection risk — each limiting the long-term utility of otherwise effective agents. Balancing efficacy against safety remains a central tension, particularly as biologic and corticosteroid-based regimens become more complex.

• Anti-drug antibody (ADA) formation and loss of response: Monoclonal antibodies carry inherent immunogenic potential, influenced by both drug- and patient-related factors. ADA formation is associated with increased infusion reactions, accelerated drug clearance, and loss of response (LOR). Sub-therapeutic drug concentrations with low ADA levels can generally be overcome with dose escalation, whereas high ADA concentrations require a switch to another therapeutic agent. In Crohn's disease patients treated with infliximab or adalimumab, loss of response occurred in 22 of 61 patients after one year of therapy, with loss of response significantly more frequent and occurring earlier in adalimumab-naïve patients versus infliximab-treated patients.

• Infection risk associated with corticosteroid use: Corticosteroids remain widely used in autoimmune and rheumatic conditions, yet observational studies have consistently shown dose-dependent increases in risk for serious infections as well as certain opportunistic infections. While randomized controlled trials of short-term and lower-dose steroids have generally shown little or no increased risk, the real-world evidence base underscores the need for vaccination and screening strategies in patients beginning chronic steroid therapy.

• Safety trade-offs with biologic dose escalation: Higher-dose biologic regimens carry distinct safety signals. In placebo-controlled trials of ocrelizumab in rheumatoid arthritis, OCR 500 mg×2 plus methotrexate was associated with a statistically significant increase in serious infectious events — a difference of 2.4 per 100 patient-years (95% CI, 0.3–4.5) versus placebo plus methotrexate — while the OCR 200 mg×2 safety profile was comparable to placebo plus methotrexate. Patients recruited in Asia exhibited a higher risk of serious infections (hazard ratio, 1.78; 95% CI, 1.03–3.06).

• Limited validated biomarkers for patient stratification: Despite the recognized value of biomarkers for predicting prognosis, dose selection, and therapeutic or adverse responses, fully validated stratification biomarkers remain scarce. Identification, qualification, and implementation of such biomarkers — particularly companion diagnostics co-developed with specific drugs — are challenging and frequently necessitate collaborative efforts.

• Unmet need for antigen-specific immune tolerance induction: The development of therapeutic approaches for robust, long-lasting, and antigen-specific immune tolerance remains an important unmet clinical need for the management of autoimmunity, allergy, organ transplantation, and gene therapy, despite recent advances in understanding tolerance mechanisms.

Th17 Cells: An Emerging Target for Autoimmune Reset

Several kinase-based signaling pathways have emerged as compelling therapeutic targets in autoimmune disease research. Bruton's tyrosine kinase (BTK), a key regulator of antigen receptor signaling in B cells and Fc receptor signaling in mast cells and macrophages, has been validated as a target through the design of potent and selective covalent BTK inhibitors. These compounds, engineered to bind an inactive conformation of BTK via a covalent warhead targeting Cys481, demonstrated excellent kinase selectivity and blocked FcγR-mediated hypersensitivity in vivo. In lupus models, BTK inhibition with the tool inhibitor M7583 reduced autoantibodies, nephritis, and mortality in BXSB-Yaa mice, and suppressed arthritis in the pristane-induced DBA/1 model — with evidence that efficacy in the latter was mediated through inhibition of Fc receptors rather than BCR signaling. Spleen tyrosine kinase (Syk) represents a parallel target of interest: CD27⁻Syk⁺⁺ memory-like B cells are found at increased frequency in systemic lupus erythematosus (SLE) patients, exhibiting enhanced BCR phosphorylation and differentiation into IgG-secreting cells. In FcγRIIb-deficient lupus mice, Syk inhibition downregulated inflammatory pathways in macrophages and attenuated sepsis severity, underscoring the therapeutic relevance of Syk signaling in lupus-associated immune dysregulation.

The neonatal Fc receptor (FcRn) has gained substantial traction as a therapeutic target in IgG autoantibody-driven diseases. FcRn normally recycles IgG by binding it in acidic endosomal vesicles and returning it to the cell surface; IgG not bound to FcRn is degraded in lysosomes. FcRn inhibitors exploit this mechanism to reduce overall plasma IgG levels — including pathogenic autoantibodies — without affecting IgA, IgE, IgM, or IgD. Approved and investigational agents in this class include efgartigimod, rozanolixizumab, batoclimab, and nipocalimab, administered either intravenously or subcutaneously. In a phase III trial in generalized myasthenia gravis (gMG), efgartigimod reduced IgG and anti-acetylcholine receptor antibody levels and improved Myasthenia Gravis Activities of Daily Living scores; efgartigimod alfa was subsequently approved in Japan in 2022 for gMG when steroids or non-steroidal immunosuppressive drugs do not lead to sufficient response. Positive clinical trial results for efgartigimod and rozanolixizumab have also led to their approval for gMG more broadly, with ongoing trials investigating these agents in chronic inflammatory demyelinating polyneuropathy, myositis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. Reported adverse events include headache, upper respiratory tract infection, urinary tract infection, diarrhea, pyrexia, and nausea; batoclimab and nipocalimab have additionally been associated with transient hypoalbuminemia and hypercholesterolemia.

Cytokine pathway modulation continues to define the frontier of autoimmune therapeutics, with the IL-23/Th17 axis occupying a central position. IL-23, composed of the IL-12p40 subunit and the IL-23p19 subunit, plays a key role in the induction of Th17 cells and is part of the broader IL-12 cytokine family — which also includes IL-12 itself and IL-27 — all of which activate JAK/STAT signaling pathways and regulate T cell differentiation. In psoriasis, the IL-23/Th17 axis is described as a "new central circuit," with TNF-alpha, IL-17 family cytokines, and IL-36 mediating keratinocyte and tissue dysfunction; biologics targeting TNF-alpha, IL-17, and IL-23 are characterized as "clinically transformative," though a large cohort of patients experience incomplete response, resistance, or challenges in long-term management. IL-36R and the aryl hydrocarbon receptor (AHR) are identified as novel targets that may extend the therapeutic opportunity in this space. In the central nervous system, IL-17RA — the receptor for IL-17A — is constitutively expressed on astrocytes and microglia, is upregulated in experimental autoimmune encephalomyelitis, and mediates chemokine secretion including MCP-1, MCP-5, MIP-2, and KC, positioning IL-17RA signaling in glial cells as a potential pathway for therapeutic intervention in CNS autoimmune inflammation.

ai3Bio's Place in the Evolving Autoimmune Treatment Landscape

The autoimmune treatment landscape has undergone substantial diversification, with Janus kinase (JAK) inhibitors and non-TNF biologics establishing complementary roles across multiple indications. In rheumatoid arthritis, a Bayesian network meta-analysis of nine RCTs (3,577 patients) demonstrated that JAK inhibitors achieved the highest ACR20 response rates in TNF-inhibitor-inadequate responders, while non-TNF biologics showed higher ACR70 response rates — with no statistically significant differences in adverse events or serious adverse events across treatments at 12 weeks. In DMARD-naïve RA patients, upadacitinib 15 mg ranked highest for ACR20 response, while tofacitinib 5 mg led for ACR50 and ACR70 responses, with baricitinib, filgotinib, and methotrexate also evaluated — again without statistically significant safety differences between groups. Long-term data have further reinforced confidence in newer agents: olokizumab combined with methotrexate maintained stable clinical response rates and a consistent safety profile through 106 weeks across 2,304 patients, with serious adverse event rates of 9.57 and 9.13 per 100 patient-years for the every-2-weeks and every-4-weeks regimens, respectively.

Beyond RA, targeted biologics have reshaped the therapeutic approach to conditions including Crohn's disease, ulcerative colitis, systemic lupus erythematosus (SLE), and psoriasis. Risankizumab-rzaa, the first selective IL-23 inhibitor approved for Crohn's disease, demonstrated significantly higher rates of clinical remission (RR 1.85; 95% CI 1.69–2.01) and endoscopic remission (RR 2.81; 95% CI 2.04–3.87) versus placebo during induction, with a 78% reduction in CD-related hospitalizations (RR 0.22; 95% CI 0.14–0.34), and maintained these effects through the maintenance phase. In ulcerative colitis, ozanimod — the first sphingosine 1-phosphate receptor modulator approved for the indication — demonstrated superiority over placebo across clinical remission, endoscopic improvement, corticosteroid-free remission, and mucosal healing endpoints in the True North Phase 3 trial. In SLE, anifrolumab (targeting type-I interferon receptors) was evaluated in the TULIP 1 and TULIP 2 trials, with the ongoing TULIP LTE trial supporting its long-term safety and efficacy, and the IRIS Phase III trial exploring its application in lupus nephritis with favorable renal responses.

Safety characterization over extended follow-up periods has become an increasingly prominent feature of recent trial programs. Ixekizumab, evaluated across 13 clinical studies totaling 17,003.4 patient-years of exposure in moderate-to-severe psoriasis, showed largely stable or declining adverse event rates over five years, including stable rates of serious adverse events (range 6.2–7.0/100 patient-years), malignancies (range 0.4–0.6/100 patient-years), and major adverse cardiovascular events (range 0.3–0.7/100 patient-years). For JAK inhibitors, a systematic literature review informing the 2022 EULAR RA recommendations identified a higher risk of herpes zoster with JAK inhibitors versus csDMARDs (adjusted HR 3.66) and bDMARDs (adjusted HR 1.9–2.3), and one safety-designed RCT reported numerically higher rates of malignancies (HR 1.48; 95% CI 1.04–2.09) and MACE (HR 1.33; 95% CI 0.91–1.94) with tofacitinib versus TNF inhibitors in patients with cardiovascular risk factors — findings that continue to shape class-level risk stratification across the JAK inhibitor landscape.

Precision Immune Reset: ai3Bio's Bold Bet on Th17

The emergence of ai3Bio, backed by substantial Series A funding, signals a compelling shift in the strategic landscape for autoimmune disease therapies. The company's commitment to an 'immune reset' by selectively targeting Th17 cells represents a sophisticated evolution from traditional broad immunosuppression. Th17 cells are recognized as central orchestrators of inflammation in various autoimmune conditions, and their selective elimination could offer a pathway to durable efficacy with a significantly improved safety profile, avoiding the systemic vulnerabilities associated with non-specific immune suppression. This approach aligns with the promise seen in advanced therapies like BCMA-directed CAR-T for autoimmune diseases, which have demonstrated precision retuning of self-reactivity without broad immune suppression.

Strategically, ai3Bio's dual-platform approach—utilizing both novel molecular delivery systems, such as microscopic fatty shells, and targeted antibody drugs—suggests a versatile pipeline capable of addressing multiple Th17-mediated indications. This could establish a strong competitive position by offering differentiated mechanisms of action and potentially more accessible delivery methods compared to complex cell therapies.

However, several critical risks must be navigated. The challenge lies in ensuring the absolute specificity of Th17 elimination, as these cells also play roles in host defense against pathogens. Off-target effects or unintended consequences of their depletion require rigorous evaluation. Furthermore, while lipid nanoparticles show promise for molecular delivery, translating this into effective and stable in vivo therapeutic delivery remains a significant hurdle. Finally, preclinical success in inhibiting Th17 activity, while encouraging, does not guarantee clinical translation, as evidenced by the varied outcomes of RORγt inhibitors in different disease models. The complex interplay of immune cells, including the Th17/Treg balance, necessitates robust clinical validation. If ai3Bio can successfully overcome these translational and specificity challenges, its innovative strategy could indeed redefine the standard of care for a wide spectrum of autoimmune diseases, offering a new era of precision immunology.